Sanofi Consumer Healthcare India Ltd
Mon 6/04/2026,15:45:46 | NSE : SANOFICONR
Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.
Market Data
Essential tool: analyze, trade, manage, decide.
Open
₹ 4505.00
Previous Close
₹ 4578.10
Volume
7396
Mkt Cap ( Rs. Cr)
₹10688.74
High
₹ 4698.00
Low
₹ 4505.00
52 Week High
₹ 5894.50
52 Week Low
₹ 3975.00
Book Value Per Share
₹ 166.75
Dividend Yield
0.00
Face Value
₹ 10.00
What’s Your Call?
Collective community sentiment on Sanofi Consumer Healthcare India Ltd
Your Vote -
Buy
81.82%
Hold
0.00%
Sell
18.18%
81.82%
11 users have voted
Market Depth
How many stocks are available to buy or sell and at what prices.
Buy Order Quantity
NaN%
Sell Order Quantity
NaN%
Bid Price
Qty
0.00
0
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
0
Bid Price
Qty
0.00
0
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
0
Option Chain
Analyzes market sentiment, predicts Sanofi Consumer Healthcare India Ltd' movement.
NO_RECORD_FOUND
News
Media spotlight triggers stock stock attention, sentiment.
-
Sanofi Consumer - Analysts/Institutional Investor Meet/Con. Call Updates
-
Sanofi Consumer - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
-
Sanofi Consumer - Analysts/Institutional Investor Meet/Con. Call Updates
-
Sanofi Consumer - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
-
Sanofi Consumer - Trading Window
-
Sanofi Consumer - Announcement under Regulation 30 (LODR)-Investor Presentation
-
Sanofi Consumer - Investor Presentation
-
Sanofi Consumer - Publication of Postal Ballot Notice
-
Sanofi Consumer - Copy of Newspaper Publication
-
Sanofi Consumer - Shareholders meeting
-
Sanofi Consumer - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
-
Sanofi Consumer - Analysts/Institutional Investor Meet/Con. Call Updates
-
Sanofi Consumer - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
-
Sanofi Consumer - Copy of Newspaper Publication
-
Sanofi Consumer Q4 net profit jumps 50.11% at Rs 66.50 cr
-
Sanofi Consumer - Change in Management
-
Sanofi Consumer - Announcement under Regulation 30 (LODR)-Change in Management
-
Sanofi Consumer - Change in Management
-
Sanofi Consumer - Press Release
-
Sanofi Consumer - Announcement under Regulation 30 (LODR)-Press Release / Media Release
-
Sanofi Consumer - Re-Appointment Of M/S. Kishore Bhatia & Associates As The Cost Auditor Of The Company For The Financial Yea
-
Sanofi Consumer - Appointment
-
Sanofi Consumer - Dividend
-
Sanofi Consumer - Corporate Action-Board approves Dividend
-
Sanofi Consumer - Outcome Of Board Meeting For Approval Of Audited Financial Results Of The Company For The Quarter And Finan
-
Sanofi Consumer - Outcome of Board Meeting
-
Sanofi Consumer - Board Meeting Outcome for Outcome Of Board Meeting For Approval Of Audited Financial Statements Of The Comp
-
Sanofi Consumer - Update on board meeting
-
Sanofi Consumer Heal - Board Meeting Intimation for For Considering And Approving Audited Financial Statements For The Quarte
-
Sanofi Consumer Heal has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2025
-
Sanofi Consumer Heal - Certificate under SEBI (Depositories and Participants) Regulations, 2018
-
Sanofi Consumer Heal - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
-
Sanofi Consumer Heal - Disclosure under SEBI Takeover Regulations
Key fundamentals
Evaluate the intrinsic value of Sanofi Consumer Healthcare India Ltd stock
| Name | December-25 | December-24 | March-24 | December-23 | |
|---|---|---|---|---|---|
| Assets | 384 | 1.7 | 1.7 | 1.7 | |
| Liabilities | 384 | 1.7 | 1.7 | 1.7 | |
| Equity | 23 | 2 | 2 | 2 | |
| Gross Profit | 309 | 0 | 0 | -0.3 | |
| Net Profit | 240.1 | 0 | 0 | -0.3 | |
| Cash From Operating Activities | 174.8 | -0.4 | -0.4 | -0.4 | |
| NPM(%) | 27.33 | 0 | 0 | 29.69 | |
| Revenue | 878.4 | 0 | 0 | 0 | |
| Expenses | 569.4 | 0 | 0 | 0.3 | |
| ROE(%) | 62.52 | 0 | 0 | -0.07 |
Corporate Action
| XD-Date | Dividend-Amount | Dividend-% | Dividend Yield(%GE) | Price on that day |
|---|---|---|---|---|
| 75 | 750 | 0 | 4009.2 | |
| 17 Apr 2025 | 55 | 550 | 0 | 4756.85 |
Peers
Other companies within the same industry or sector that are comparable to Sanofi Consumer Healthcare India Ltd
| Company | Price | Price (% change) | pe(x) | EV/EBITDA(x) | ROE(%) | ROCE(%) |
|---|---|---|---|---|---|---|
| Sharda Cropchem Ltd | 915.00 | 3.12 | 14.59 | 41903.81 | 337.37 | 0.98 |
| Amines and Plasticizers Ltd | 146.18 | 3.85 | 23.65 | 25554.59 | 372.61 | 0.34 |
| Indogulf Cropsciences Ltd | 63.64 | -2.59 | 10.54 | 22659.61 | 49.78 | 0.00 |
| Grauer and Weil (India) Ltd | 115.60 | 0.00 | 37.41 | 210591.74 | 346.70 | 0.43 |
Company Info
The Company was incorporated as a public limited company under the Companies Act, 2013, pursuant to a certificate of incorporation dated May 10, 2023, issued by the Registrar of Companies, Central Registration Centre. Major Events and Milestones:2023 Incorporation of the Company 2024 Demerger, transfer and vesting of the Demerged Undertaking from Sanofi India Limited into the Company on a going concern basis pursuant to the Scheme 2020 -Sanofi renews partnership with the WHO to fight Neglected Tropical Diseases and eliminate sleeping sickness before 2030. 2021 -Sanofi completed acquisition of Kadmon. -Sanofi completed acquisition of Translate Bio, accelerating the application of mRNA in new vaccines and therapeutics. -Sanofi launched its new global employee share ownership plan. -Sanofi established three-year collaboration with Stanford Medicine to accelerate immunology research. 2022 -Sanofi and Innate Pharma expand collaboration for natural killer cell therapeutics in oncology. -Sanofi-GSK first to report a successful efficacy study against Omicron with COVID-19 Beta-containing vaccine. -Sanofi launches its first Digital Accelerator fueled by new talent and focused on growth. -Sanofi recognized by S&P as one of the most sustainability- committed companies. -Sanofi launches first-in-pharma Diversity, Equity & Inclusion Board. 2023 -Sanofi's Consumer Healthcare Unit launches the Shared Care Collective, an advisory group working to advance sustainability. -Sanofi completes acquisition of Qunol. -Sanofi completes acquisition of Provention Bio, Inc. - Sanofi Consumer Healthcare launches new portal to unlock science and solve key challenges in self-care. 2024 -Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline. 2025-Sanofi's breakthrough therapy Rezurockr approved in India for treating patients living with chronic graft-versus-host disease.
The Company was incorporated as a public limited company under the Companies Act, 2013, pursuant to a certificate of incorporation dated May 10, 2023, issued by the Registrar of Companies, Central Registration Centre. Major Events and Milestones:2023 Incorporation of the Company 2024 Demerger, transfer and vesting of the Demerged Undertaking from Sanofi India Limited into the Company on a going concern basis pursuant to the Scheme 2020 -Sanofi renews partnership with the WHO to fight Neglected Tropical Diseases and eliminate sleeping sickness before 2030. 2021 -Sanofi completed acquisition of Kadmon. -Sanofi completed acquisition of Translate Bio, accelerating the application of mRNA in new vaccines and therapeutics. -Sanofi launched its new global employee share ownership plan. -Sanofi established three-year collaboration with Stanford Medicine to accelerate immunology research. 2022 -Sanofi and Innate Pharma expand collaboration for natural killer cell therapeutics in oncology. -Sanofi-GSK first to report a successful efficacy study against Omicron with COVID-19 Beta-containing vaccine. -Sanofi launches its first Digital Accelerator fueled by new talent and focused on growth. -Sanofi recognized by S&P as one of the most sustainability- committed companies. -Sanofi launches first-in-pharma Diversity, Equity & Inclusion Board. 2023 -Sanofi's Consumer Healthcare Unit launches the Shared Care Collective, an advisory group working to advance sustainability. -Sanofi completes acquisition of Qunol. -Sanofi completes acquisition of Provention Bio, Inc. - Sanofi Consumer Healthcare launches new portal to unlock science and solve key challenges in self-care. 2024 -Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline. 2025-Sanofi's breakthrough therapy Rezurockr approved in India for treating patients living with chronic graft-versus-host disease.
Read More
Parent Organisation
Sanofi Consumer Healthcare India Ltd.
Founded
10/05/2023
Managing Director
Mr.Himanshu Bakshi
NSE Symbol
SANOFICONREQ
FAQ
The current price of Sanofi Consumer Healthcare India Ltd is ₹ 4641.10.
The 52-week high for Sanofi Consumer Healthcare India Ltd is ₹ 4698.00 and the 52-week low is ₹ 4505.00.
The market capitalization of Sanofi Consumer Healthcare India Ltd is currently ₹ 10688.74. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.
To buy Sanofi Consumer Healthcare India Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.
To invest in Sanofi Consumer Healthcare India Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Sanofi Consumer Healthcare India Ltd shares.
The CEO of Sanofi Consumer Healthcare India Ltd is Mr.Himanshu Bakshi, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.
